Uterine Sarcomas: How to Navigate an Ever-Growing List of Subtypes
Authors:
- 1 July 2022
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 42 (42) , 910-919
Abstract
Uterine sarcomas are rare mesenchymal tumors that are aggressive cancers. The rarity of these tumors, and consequently limited prospective data, has made surgical management of uterine sarcomas challenging. One major obstacle in the management of uterine sarcomas is establishing the diagnosis prior to surgery, which is crucial for appropriate intraoperative management. This paper serves to review aspects of surgical management of uterine sarcomas that remain unanswered. Distinguishing common benign myomas from rare uterine sarcomas is important for operative planning and subspecialty care because benign myomas are frequently managed with minimally invasive hysterectomy or myomectomy, whereas the mainstay of management of uterine sarcomas is hysterectomy without specimen fragmentation. Preoperative clinical presentation, serum studies, imaging, and histologic examination all have limitations in establishing a preoperative diagnosis. In addition, patients are often of reproductive age and desire fertility preservation. Although surgery remains the cornerstone for management, high-quality data guiding best practices are sparse. Morcellation should be avoided. Expert pathologic review, imaging to assess for metastatic disease, and consideration of hormone receptor testing are advisable. Recent data have further informed surgical approach and fertility preservation in early-stage disease, but controversy remains. Despite substantial advancement in the medical management of uterine sarcomas, surgical management of uterine sarcomas remain challenging. Larger studies with long-term follow-up are needed to guide fertility preservation surgery options, both local resection and ovarian preservation, further in young women. Development of novel methods to differentiate between benign and malignant uterine masses is needed.Keywords
This publication has 67 references indexed in Scilit:
- Endometrial Stromal SarcomaObstetrics & Gynecology, 2013
- Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal NeoplasmsPLOS ONE, 2012
- New Challenges in Detecting, Grading, and Staging Endometrial Cancer After Uterine MorcellationJournal of Minimally Invasive Gynecology, 2012
- Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosisGynecologic Oncology, 2012
- Short-term change in growth of uterine leiomyoma: tumor growth spurtsFertility and Sterility, 2011
- Laparoscopic HysterectomyClinical Obstetrics and Gynecology, 2009
- Cause-Specific Mortality in Long-Term Survivors of RetinoblastomaJNCI: Journal of the National Cancer Institute, 2009
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008
- A multi-institutional review of outcomes of endometrial stromal sarcomaGynecologic Oncology, 2007
- Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?Journal of Clinical Pathology, 2002